Delivery of Single siRNA Molecules - Nanotechnology for the Delivery of Therapeutic Nucleic Acids - page 105

27. Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K.,
Breen, W.,

et al . (2005). Potent and persistent in vivo anti-HBV activity

, pp. 1002-1007.
28. Moschos, S. A., Jones, S. W., Perry, M. M., Williams, A. E., Erjefalt, J. S.,
Turner, J. J.,

of chemically modified siRNAs, Nat . Biotechnol . 23

. (2007). Lung delivery studies using siRNA conjugated
to TAT(48-60) and penetratin reveal peptide induced reduction in
gene expression and induction of innate immunity,

et al

Bioconjug . Chem .

, pp. 1450-1459.
29. Nagahara, H., Vocero-Akbani, A. M., Snyderm E. L., Ho, A., Latham, D.
G., Lissy, N. A.,

18

. (1998). Transduction of full-length TAT fusion
proteins into mammalian cells: TAT-p27Kip1 induces cell migration,
Nat

et al

, pp. 1449-1452.
30. Palm-Apergi, C., Lorents, A., Padari, K., Pooga, M., and Hällbrink, M.
(2009). The membrane repair response masks membrane disturbances
caused by cell-penetrating peptide uptake,

. Med . 4

, pp. 214-223.
31. Palm-Apergi, C., Eguchi, A., and Dowdy, S. F. (2011). PTD-DRBD siRNA
delivery,

FASEB J . 23

, pp. 339-347.
32. Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., and Sood,
A. K. (2011). RNA interference in the clinic: challenges and future
directions,

Methods Mol . Biol . 683

, pp. 59-67.
33. Rappaport, J., Hanss, B., Kopp, J. B., Copeland, T. D., Bruggeman,
L. A., Coffman, T. M.,

Nat . Rev . Cancer . 11

. (1995). Transport of phosphorothioate
oligonucleotides in kidney: implications for molecular therapy,

et al

Kidney

, pp. 1462-1469.
34. Richard, J. P., Melikov, K., Brooks, H., Prevot, P., Lebleu, B., Chernomordik,
L. V.,

Int . 47

. (2005). Cellular uptake of unconjugated TAT peptide involves
clathrin-dependent endocytosis and heparan sulfate receptors,

et al

J . Biol .

, pp. 15300-15306.
35. Robbins, M., Judge, A., Liang, L., McClintock, K., Yaworski, E., and
MacLachlan, I. (2007). 2

Chem . 280

′

-O-Methyl-modified RNAs act as TLR7

, pp. 1663-1669.
36. Ryter, J. M., and Schultz, S. C. (1998). Molecular basis of double-
stranded RNA-protein interactions: structure of a dsRNA-binding
domain complexed with dsRNA,

antagonists, Mol . Ther . 15

, pp. 7505-7513.
37. Snyder, E. L., and Dowdy, S. F. (2004). Cell penetrating peptides in drug
delivery,

EMBO J . 17

, pp. 389-393.
38. St Johnston, D., Brown, N. H., Gall, J. G., and Jantsch, M. (1992). A
conserved double-stranded RNA-binding domain,

Pharm . Res . 21

Proc . Natl . Acad . Sci .

89 , pp. 10979-10983.